Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA1 | P30542 | 2/20 | 0.56 |
| ▸ | SCN4A | P35499 | 1/20 | 0.53 |
| ▸ | GRAMD1A | Q96CP6 | 1/20 | 0.53 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.50 |
| ▸ | SCN3A | Q9NY46 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 3/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.48 |
| ▸ | RAD52 | P43351 | 1/20 | 0.48 |
| ▸ | RECQL | P46063 | 1/20 | 0.48 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.47 |
| ▸ | GCK | P35557 | 6/20 | 0.43 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.42 |
| ▸ | PRKCI | P41743 | 1/20 | 0.41 |
| ▸ | MKNK1 | Q9BUB5 | 2/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31409422 | 0.92 | SCN4A (0.53) | ADORA1SCN4AGRAMD1ASCN5ASCN3A | |
| SCHEMBL15001583 | 0.91 | SCN4A (0.51) | ADORA1SCN4AGRAMD1ASCN5ASCN3A | |
| SCHEMBL17376986 | 0.90 | ADORA1 (0.53) | ADORA1SCN4AGRAMD1ASCN5ASCN3A | |
| SCHEMBL741852 | 0.88 | ADORA1 (0.47) | ADORA1SCN4AGRAMD1ASCN5ASCN3A | |
| SCHEMBL17993838 | 0.85 | GRAMD1A (0.53) | ADORA1GRAMD1AMAPTKDM4ENR1H2 | |
| SCHEMBL12761195 | 0.85 | GRAMD1A (0.53) | ADORA1GRAMD1AMAPTKDM4ENR1H2 | |
| SCHEMBL165650 | 0.85 | GRAMD1A (0.53) | ADORA1GRAMD1AMAPTKDM4ENR1H2 | |
| SCHEMBL17933982 | 0.85 | RAD52 (0.51) | ADORA1SCN4AGRAMD1ASCN5ASCN3A | |
| SCHEMBL31143542 | 0.85 | ADORA1 (0.51) | ADORA1SCN4AGRAMD1AMAPTKDM4E | |
| SCHEMBL2699291 | 0.84 | GRAMD1A (0.53) | ADORA1GRAMD1AMAPTKDM4ENR1H2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 290 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260138991-A1 | SEMI-SATURATED BICYCLIC DERIVATIVES AND RELATED USES | MOMA THERAPEUTICS INC (US) | 2026-05-21 | — | — | US | disclosed |
| EP-4705298-A2 | SEMI-SATURATED BICYCLIC DERIVATIVES AND RELATED USES | Moma Therapeutics, Inc. (US) | 2026-03-11 | — | — | EP | disclosed |
| US-12559508-B2 | Semi-saturated bicyclic derivatives and related uses | MOMA THERAPEUTICS, INC. (US) | 2026-02-24 | — | — | US | disclosed |
| EP-4692057-A1 | NOVEL B0AT1 INHIBITOR | Mitsubishi Tanabe Pharma Corporation (JP) | 2026-02-11 | — | — | EP | disclosed |
| US-20260001849-A1 | NOVEL B0AT1 INHIBITOR | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2026-01-01 | — | — | US | disclosed |
| US-20250388604-A1 | Compounds and Their Use as PDE4 Activators | MIRONID LIMITED (GB) | 2025-12-25 | — | — | US | disclosed |
| US-20250230171-A1 | SEMI-SATURATED BICYCLIC DERIVATIVES AND RELATED USES | MOMA THERAPEUTICS, INC. | 2025-07-17 | — | — | US | disclosed |
| EP-4572762-A1 | COMPOUNDS AND THEIR USE AS PDE4 ACTIVATORS | Mironid Limited (GB) | 2025-06-25 | — | — | EP | disclosed |
| US-20250066344-A1 | BENZOTHIAZOLE, BENZOISOXAZOLE, AND BENZODIOXOLE ANALOGS AS RXFP1 RECEPTOR AGONISTS | BRISTOL MYERS SQUIBB CO (US) | 2025-02-27 | — | — | US | disclosed |
| US-20240409533-A1 | HMOX1 INDUCERS | Astellas Engineered Small Molecules US, Incorporated | 2024-12-12 | — | — | US | disclosed |
| WO-2006108709-A1 | 3-SULFONYLAMINO-PYRROLIDINE-2-ONE DERIVATIVES AS FACTOR XA INHIBITORS | GLAXO GROUP LIMITED (GB) | 2006-10-19 | — | — | WO | disclosed |
| US-20060223849-A1 | Benzazole derivatives, compositions, and methods of use as beta-secretase inhibitors | HIGH POINT PHARMACEUTICALS, LLC | 2006-10-05 | — | — | US | disclosed |
| WO-2006099379-A2 | BENZAZOLE DERIVATIVES, COMPOSITIONS, AND METHODS OF USE AS B-SECRETASE INHIBITORS | TRANSTECH PHARMA, INC. (US) | 2006-09-21 | — | — | WO | disclosed |
| US-20060004009-A1 | Ethylenediamine derivatives | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2006-01-05 | — | — | US | disclosed |
| EP-1577301-A1 | DIAMINE DERIVATIVES | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2005-09-21 | — | — | EP | disclosed |
| EP-1577302-A1 | NOVEL ETHYLENEDIAMINE DERIVATIVES | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2005-09-21 | — | — | EP | disclosed |
| EP-1562958-A1 | N-SULFONYLAMINOTHIAZOLE | Novartis AG (CH) | 2005-08-17 | — | — | EP | disclosed |
| US-20040122063-A1 | Ethylenediamine derivatives | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2004-06-24 | — | — | US | disclosed |
| WO-2004043968-A1 | N-SULFONYLAMINOTHIAZOLE | NOVARTIS AG (CH) | 2004-05-27 | — | — | WO | disclosed |
| EP-1270557-A1 | ETHYLENEDIAMINE DERIVATIVES | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2003-01-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260001849-A1 | NOVEL B0AT1 INHIBITOR | BCAT1, BCAT2, BHMT | ADORA1 1507/4885SCN4A 1857/4885GRAMD1A 3675/4885 |
| US-20060004009-A1 | Ethylenediamine derivatives | F2, ECE1, MLLT1 | ADORA1 1447/4885SCN4A 368/4885GRAMD1A 1049/4885 |
| US-20250230171-A1 | SEMI-SATURATED BICYCLIC DERIVATIVES AND RELATED USES | POLQ, POLB, POLK | ADORA1 2194/4885SCN4A 2873/4885GRAMD1A 2841/4885 |
| US-20260138991-A1 | SEMI-SATURATED BICYCLIC DERIVATIVES AND RELATED USES | POLA1, SUB1, CTDSP1 | ADORA1 192/4885SCN4A 1136/4885GRAMD1A 3607/4885 |
| US-12559508-B2 | Semi-saturated bicyclic derivatives and related uses | POLA1, CTDSP1, SUB1 | ADORA1 301/4885SCN4A 1310/4885GRAMD1A 2932/4885 |
| US-20240409533-A1 | HMOX1 INDUCERS | HMOX1, HMOX2, HMBS | ADORA1 1923/4885SCN4A 4427/4885GRAMD1A 4137/4885 |
| US-20250388604-A1 | Compounds and Their Use as PDE4 Activators | PDE4A, PDE7A, PDE4B | ADORA1 113/4885SCN4A 56/4885GRAMD1A 4161/4885 |
| US-20060223849-A1 | Benzazole derivatives, compositions, and methods of use as beta-secretase inhibitors | BACE1, BACE2, APP | ADORA1 1923/4885SCN4A 2372/4885GRAMD1A 3545/4885 |
| US-20250066344-A1 | BENZOTHIAZOLE, BENZOISOXAZOLE, AND BENZODIOXOLE ANALOGS AS RXFP1 RECEPTOR AGONISTS | RXFP1, RXFP2, RXFP3 | ADORA1 602/4885SCN4A 3723/4885GRAMD1A 3105/4885 |
| US-20040122063-A1 | Ethylenediamine derivatives | ECE1, F2, ECE2 | ADORA1 1150/4885SCN4A 1233/4885GRAMD1A 1143/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.